Mafosfamide, a cyclophosphamide analog, causes a proinflammatory response and increased permeability on endothelial cells in vitro
- 13 January 2023
- journal article
- research article
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 58 (4) , 407-413
Abstract
Post-transplantation cyclophosphamide (PTCy) has decreased GVHD incidence. Endothelial damage in allo-HCT is caused by multiple factors, including conditioning treatments and some immunosupressants, and underlies HCT-complications as GVHD. Nevertheless, the specific impact of PTCy on the endothelium remains unclear. We evaluated the effect of mafosfamide (MAF), an active Cy analog, on endothelial cells (ECs) vs. cyclosporine A (CSA), with known damaging endothelial effect. ECs were exposed to MAF and CSA to explore changes in endothelial damage markers: (i) surface VCAM-1, (ii) leukocyte adhesion on ECs, (iii) VE-cadherin expression, (iv) production of VWF, and (v) activation of intracellular signaling proteins (p38MAPK, Akt). Results obtained (expressed in folds vs. controls) indicate that both compounds increased VCAM-1 expression (3.1 ± 0.3 and 2.8 ± 0.6, respectively, p < 0.01), with higher leukocyte adhesion (5.5 ± 0.6, p < 0.05, and 2.8 ± 0.4, respectively). VE-cadherin decreased with MAF (0.8 ± 0.1, p < 0.01), whereas no effect was observed with CSA. Production of VWF augmented with CSA (1.4 ± 0.1, p < 0.01), but diminished with MAF (0.9 ± 0.1, p < 0.05). p38MAPK activation occurred with both compounds, being more intense and faster with CSA. Both drugs activated Akt, with superior MAF effect at longer exposure. Therefore, the cyclophosphamide analog MAF is not exempt from a proinflammatory effect on the endothelium, though without modifying the subendothelial characteristics.Keywords
All Related Versions
Funding Information
- Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (FIS PI19/00888)
- Generalitat de Catalunya (2017-SGR675, CERCA)
This publication has 68 references indexed in Scilit:
- Fiji: an open-source platform for biological-image analysisNature Methods, 2012
- The role of the endothelium in the short-term complications of hematopoietic SCTBone Marrow Transplantation, 2011
- Cyclophosphamide Chemotherapy Sensitizes Tumor Cells to TRAIL-Dependent CD8 T Cell-Mediated Immune Attack Resulting in Suppression of Tumor GrowthPLOS ONE, 2009
- Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009Bone Marrow Transplantation, 2009
- HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation CyclophosphamideTransplantation and Cellular Therapy, 2008
- Apoptotic death induced by the cyclophosphamide analogue mafosfamide in human lymphoblastoid cells: Contribution of DNA replication, transcription inhibition and Chk/p53 signalingToxicology and Applied Pharmacology, 2008
- Phenotypic heterogeneity is an evolutionarily conserved feature of the endotheliumBlood, 2006
- Clinical Pharmacokinetics of CyclophosphamideClinical Pharmacokinetics, 2005
- Cyclosporine is required to prevent severe acute GVHD following T-cell-depleted peripheral blood stem cell transplantationBone Marrow Transplantation, 2003
- CsA-based post-graft immunosuppression: the main factor for improving outcome of allografted patients with acquired aplastic anemia. A retrospective survey by the Spanish Group of Hematopoietic TransplantationBone Marrow Transplantation, 2002